Lumos Pharma to Participate in Upcoming Investor Conferences
Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company focused on rare diseases, will participate in two notable conferences in March 2022. The 34th Annual Roth Conference takes place from March 13-15, featuring a live fireside chat on March 14 at 10:30 AM PDT. Additionally, the Maxim 2022 Virtual Growth Conference is scheduled for March 28-30, with a pre-recorded presentation available from March 28 at 9:00 AM EDT. Investors can access the webcasts through Lumos Pharma's website and contact their investor relations for one-on-one meetings.
- None.
- None.
AUSTIN, Texas, March 10, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company will participate in the 34th Annual Roth Conference and the Maxim 2022 Virtual Growth Conference in March.
| Event: | 34th Annual Roth Conference – March 13-15 | ||
| Presentation: | Live fireside chat March 14th at 10:30 AM PDT / 1:30 PM EDT | ||
| Webcast link: | Here | ||
| Event: | Maxim 2022 Virtual Growth Conference – March 28-30 | ||
| Presentation: | Pre-recorded presentation available beginning March 28th at 9:00 AM (EDT) | ||
| Webcast link: | Here on the M-Vest conference platform |
The webcasts for each presentation can also be found on the Company’s website under “Events & Presentations” in the Investors & Media section where a replay of each presentation will be also be available. Please contact your Roth or Maxim salesperson, or Lumos Pharma Investor Relations, to schedule one-on-one meetings with the management team during the conferences or thereafter.
About Lumos Pharma
Lumos Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare diseases. Lumos Pharma was founded and is led by a management team with longstanding experience in rare disease drug development and received early funding from leading healthcare investors, including Deerfield Management, a fund managed by Blackstone Life Sciences, Roche Venture Fund, New Enterprise Associates (NEA), Santé Ventures, and UCB. Lumos Pharma’s lead therapeutic candidate is LUM-201, an oral growth hormone stimulating small molecule, currently being evaluated in a Phase 2 clinical trial, the OraGrowtH210 Trial, and a PK/PD trial, the OraGrowtH212 Trial, for the treatment of Pediatric Growth Hormone Deficiency (PGHD). If approved by the FDA, LUM-201 would provide an orally administered alternative to recombinant growth hormone injections that PGHD patients otherwise endure for many years of treatment. LUM-201 has received Orphan Drug Designation in both the US and EU. For more information, please visit https://lumos-pharma.com/.
Investor & Media Contact:
Lisa Miller
Lumos Pharma Investor Relations
512-792-5454
ir@lumos-pharma.com
Source: Lumos Pharma, Inc.
FAQ
What will Lumos Pharma present at the 34th Annual Roth Conference?
When is the Maxim 2022 Virtual Growth Conference?
What time will Lumos Pharma's presentation be available at the Maxim Conference?
Where can I find the webcasts for Lumos Pharma's presentations?
What is LUM-201 and its significance for Lumos Pharma?
